Who are Azilsartan medoxomil and hydrochlorothiazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: losartan +/- HCTZ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azilsartan-medoxomil-and-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Azilsartan medoxomil and hydrochlorothiazide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azilsartan medoxomil and hydrochlorothiazide (Azilsartan medoxomil and hydrochlorothiazide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB) + thiazide diuretic combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker (ARB) + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Azilsartan medoxomil and hydrochlorothiazide (Azilsartan medoxomil and hydrochlorothiazide) — Takeda. Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azilsartan medoxomil and hydrochlorothiazide TARGET	Azilsartan medoxomil and hydrochlorothiazide	Takeda	phase 3	Angiotensin II receptor blocker (ARB) + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Comparator: losartan +/- HCTZ	Comparator: losartan +/- HCTZ	Organon and Co	phase 3	Angiotensin II receptor blocker (ARB) + thiazide diuretic combination	AT1 angiotensin II receptor; sodium-chloride cotransporter (HCTZ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) + thiazide diuretic combination class)

Organon and Co · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azilsartan medoxomil and hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/azilsartan-medoxomil-and-hydrochlorothiazide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab